`Lu, John; Trials
`Jeffries, Andrea W.; Geers, Sarah A.; IPR2023-00760; Hughes, Diane L.; PTABDocketL2Y7; PTABDocketG2F1;
`PTABDocketC3L8; PTABDocketG3S7; PTABDocketG3D7
`RE: IPR2023-00760: Miltenyi Biomedicine GmbH v. Fred Hutchinson Cancer Center
`Thursday, July 6, 2023 10:59:47 AM
`image003.png
`
`From:
`To:
`Cc:
`
`Subject:
`Date:
`Attachments:
`
`Counsel,
`
`From the Board –
`
`Petitioner is authorized to file a ten-page reply to the POPR to address the topics identified in the
`email below. The reply must be filed by July 17, 2023.
`
`Patent Owner is authorized to file a ten-page sur-reply to Petitioner’s reply to address the
`arguments raised in the reply. The reply must be filed by July 31, 2023.
`
`No new evidence is allowed with the briefing.
`
`No conference is necessary at this time.
`
`Regards,
`
`Esther Goldschlager
`Supervisory Paralegal Specialist
`Patent Trial & Appeal Board
`U.S. Patent & Trademark Office
`
`From: Lu, John <jlu@orrick.com>
`Sent: Wednesday, July 5, 2023 2:38 PM
`To: Trials <Trials@USPTO.GOV>
`Cc: Jeffries, Andrea W. <ajeffries@jonesday.com>; Geers, Sarah A. <sgeers@jonesday.com>;
`IPR2023-00760 <IPR2023-00760@jonesday.com>; Hughes, Diane L. <dlhughes@JonesDay.com>;
`PTABDocketL2Y7 <PTABDocketL2Y7@orrick.com>; PTABDocketG2F1
`<PTABDocketG2F1@orrick.com>; PTABDocketC3L8 <PTABDocketC3L8@orrick.com>;
`PTABDocketG3S7 <PTABDocketG3S7@orrick.com>; PTABDocketG3D7
`<PTABDocketG3D7@orrick.com>
`Subject: IPR2023-00760: Miltenyi Biomedicine GmbH v. Fred Hutchinson Cancer Center
`
`CAUTION: This email has originated from a source outside of USPTO. PLEASE CONSIDER THE SOURCE before
`responding, clicking on links, or opening attachments.
`
`Dear Board,
`
`I am lead counsel for Petitioner in Miltenyi Biomedicine GmbH v. Fred Hutchinson Cancer
`Center, IPR2023-00760. Last week, Patent Owner submitted a Preliminary Response.
`Petitioner requests a ten-page reply brief to address three issues raised by the POPR,
`identified below, and would agree to an equal-length sur-reply from Patent Owner in
`
`Exhibit 3001
`
`
`
`response. Petitioner has conferred with Patent Owner (copied on this email), who believes
`additional briefing to be unnecessary. The parties disagree about whether these proposed
`topics for reply briefing were reasonably foreseeable.
`
`Petitioner’s three proposed topics for reply briefing are:
`
`1. Whether “Singh-3” (Ex. 2001), a post-priority date publication, and “Singh-2” (Ex.
`2003) discuss the same composition as Singh 2008 (Ex. 1003)
`2. The law of anticipation as it applies to whether in-vivo data is required for Singh 2008
`3. How, if at all, Ex. 2014, should be evaluated by the Board for transduction efficacy
`
`The parties are available for a conference call on Thursday between 11am – 1pm ET and
`Friday between 11am – 3pm ET, should the Board wish to further discuss these matters.
`
`Sincerely,
`Yite John Lu
`Lead Counsel for Petitioner Miltenyi
`Reg. No. 63,158
`
`John Lu
`Partner
`
`Orrick
`Los Angeles
`T (213) 612-2374
`M (510) 325-4415
`jlu@orrick.com
`
`NOTICE TO RECIPIENT | This e-mail is meant for only the intended recipient of the transmission, and may be a
`communication privileged by law. If you received this e-mail in error, any review, use, dissemination, distribution, or copying
`of this e-mail is strictly prohibited. Please notify us immediately of the error by return e-mail and please delete this message
`from your system. Thank you in advance for your cooperation.
`
`For more information about Orrick, please visit http://www.orrick.com.
`
`In the course of our business relationship, we may collect, store and transfer information about you. Please see our privacy
`policy at https://www.orrick.com/Privacy-Policy to learn about how we use this information.
`
`